XENON PHARMACEUTICALS INC (XENE) Stock Price & Overview
NASDAQ:XENE • CA98420N1050
Current stock price
The current stock price of XENE is 55.24 USD. Today XENE is down by -0.31%. In the past month the price decreased by -0.52%. In the past year, price increased by 46.84%.
XENE Key Statistics
- Market Cap
- 5.096B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.36
- Dividend Yield
- N/A
XENE Stock Performance
XENE Stock Chart
XENE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to XENE. When comparing the yearly performance of all stocks, XENE is one of the better performing stocks in the market, outperforming 87.14% of all stocks.
XENE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XENE. No worries on liquidiy or solvency for XENE as it has an excellent financial health rating, but there are worries on the profitability.
XENE Earnings
XENE Forecast & Estimates
26 analysts have analysed XENE and the average price target is 81.42 USD. This implies a price increase of 47.39% is expected in the next year compared to the current price of 55.24.
For the next year, analysts expect an EPS growth of -11.36% and a revenue growth -42.77% for XENE
XENE Groups
Sector & Classification
XENE Financial Highlights
Over the last trailing twelve months XENE reported a non-GAAP Earnings per Share(EPS) of -4.36. The EPS decreased by -44.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.63% | ||
| ROE | -59.46% | ||
| Debt/Equity | 0 |
XENE Ownership
XENE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XENE
Company Profile
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Company Info
IPO: 2014-10-17
XENON PHARMACEUTICALS INC
3650 Gilmore Way
Vancouver BRITISH COLUMBIA V5G 48W CA
CEO: Simon Pimstone
Employees: 358
Phone: 16044843300
XENON PHARMACEUTICALS INC / XENE FAQ
What does XENON PHARMACEUTICALS INC do?
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
What is the stock price of XENON PHARMACEUTICALS INC today?
The current stock price of XENE is 55.24 USD. The price decreased by -0.31% in the last trading session.
Does XENON PHARMACEUTICALS INC pay dividends?
XENE does not pay a dividend.
What is the ChartMill rating of XENON PHARMACEUTICALS INC stock?
XENE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of XENE stock?
XENON PHARMACEUTICALS INC (XENE) operates in the Health Care sector and the Biotechnology industry.
How many employees does XENON PHARMACEUTICALS INC have?
XENON PHARMACEUTICALS INC (XENE) currently has 358 employees.
Can you provide the market cap for XENON PHARMACEUTICALS INC?
XENON PHARMACEUTICALS INC (XENE) has a market capitalization of 5.10B USD. This makes XENE a Mid Cap stock.